Shanghai Bovax Biotechnology Co., Ltd. (hereafter referred as to "Shanghai Bovax"), established in December 2012,is a National High-tech Enterprise specializing in the R&D of innovative recombinant protein vaccines and drugs.
Shanghai Bovax is located at Building 12, Lane 908, Ziping Road, Yigu Plus, International Medical Park, Shanghai, China. It has a 3000m2 GMP-compliant independent R&D center for  R&D, pilot-trial, non-clinical and clinical study of innovative drugs and vaccines. The major equipment and instruments were purchased from renowned global companies. Shanghai Bovax employs more than 70 R&D professionals, more than 50% of them have master's or higher degrees. The company has obtained the qualification of Shanghai Bio Safety Level-2 Laboratory (BSL-2). It was the undertaking company of The Science and Technology Major Project of "Significant New Drugs Development" of the Ministry of Science and Technology of China during "The 13th Five-Year Plan", as well as "The Science and Technology Innovation Action Plan" of Shanghai.  
The wholly-owned subsidiary of Shanghai Bovax, Chongqing Bovax Biopharmaceutical Co.,Ltd, was established in Chongqing and has completed construction and put into use.

Shanghai Bovax has mastered the international advanced genetic engineering recombinant Virus-Like Particles technology (VLPs technology), and has developed an innovative recombinant Hansenula polymorpha expression system for effective production recombinant VLPs in eukaryocyte. Based on the VLPs technology platform, Bovax has carried out a series of vaccine R&D projects.Currently, the 4-valent and 9-valent HPV vaccines have entered the Phase III clinical stage, the 15-valent HPV vaccine was approved for clinical trials, and the recombinant EV71 vaccine is in Phase I clinical stage. Among them, the 9-valent HPV vaccine is the first of its kind to enter Phase III clinical trials in China. Furthermore, Shanghai Bovax initiated the R&D pipelines of therapeutic drugs for diabetes in 2015, which enabled the company enter the field of recombinant proteins drugs.

The core team of Shanghai Bovax consists of several senior vaccine researchers who have extensive experience in vaccine R&D and production. Their professional abilities cover a wide range of areas including project management, project design, process research, quality research, production, clinical studies, and strategic cooperation. Shanghai Bovax places a strong emphasis on intellectual property protection, and actively applies for patents and promotes relative applications in scientific and technological achievements. Currently, Shanghai Bovax holds 13 granted patents. It is expected that Bovax will successively submit the marketing authorization application for recombinant protein vaccines and drugs within the next 5 years.



Shanghai Bovax Working Environment
核心竞争力是人才与技术